Skip to content
Companies

AdvanCell

Lead-212 alpha therapies for prostate and other cancers

Raised to date

$218.3M

of $315M offered across 1 Form D filing

Still open
$96.7M
Investors
41
Last filed
Jul 16, 2026

About

AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of lead-212 (212Pb)-based targeted alpha therapies for cancer, including prostate, breast, and lung cancer. Its platform addresses the industry's biggest constraint, reliable and scalable isotope supply, with proprietary 212Pb production technology and manufacturing facilities. In July 2026 it closed an oversubscribed US$315 million Series D led by Ally Bridge Group to take its lead prostate cancer program, ADVC001, into Phase III and to expand clinical and commercial manufacturing, including a 128,000-square-foot US hub in Andover, Massachusetts. The company, founded in Australia in 2019, also has a strategic collaboration with Eli Lilly on novel targeted alpha therapies.

Vertically integrated 212Pb isotope production that gives it daily access to the alpha-emitting isotope, solving the supply bottleneck that constrains targeted alpha therapy development at scale.

Funding

  • EquityFiled Jul 16, 2026Form D
    $218.3M/ $315M

Product

ADVC001

Clinical-stage therapeutic

A 212Pb-based targeted alpha therapy for prostate cancer, advancing toward Phase III development on the back of the 2026 Series D financing.

  • Lead-212 (212Pb) targeted alpha therapy
  • Lead program in prostate cancer moving toward Phase III
  • Backed by proprietary, scalable 212Pb isotope production

Built for

Cancer patients, initially men with prostate cancer, treated through hospitals and nuclear medicine centers once therapies are approved

People on file